SuspendedNCT06705478
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Medication studyAges 18–70Multiple countriesDepression
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
- Listed locations
- Birmingham and 40 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 17, 2026
- Recruitment status
- Suspended
- Enrollment listed in the registry
- 186
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Botswana, Brazil, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT06705478
- Official title
Show the full official title
An Open-Label, Randomized Controlled Trial of Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Recruitment & locations
SuspendedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Los Angeles, United States · San Diego, United States
36 more locations
- San Francisco, United States
- Torrance, United States
- Aurora, United States
- Washington D.C., United States
- Atlanta, United States
- Chicago, United States
- Boston, United States
- St Louis, United States
- Newark, United States
- New York, United States
- Rochester, United States
- Chapel Hill, United States
- Greensboro, United States
- Cincinnati, United States
- Cleveland, United States
- Columbus, United States
- Philadelphia, United States
- Pittsburgh, United States
- Nashville, United States
- Houston, United States
- Gaborone, Botswana
- Porto Alegre, Brazil
- Rio de Janeiro, Brazil
- Pune, India
- Eldoret, Kenya
- Kericho, Kenya
- Blantyre, Malawi
- Mexico City, Mexico
- Lima, Peru
- Dasmariñas, Philippines
- Mount Edgecombe, South Africa
- Pathum Wan, Thailand
- Chiang Mai, Thailand
- Kampala, Uganda
- Hanoi, Vietnam
- Milton Park, Zimbabwe
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Allergy and Infectious Diseases (NIAID), a research institute.
Does this study involve medication?
Yes. The study involves medication, including Pramipexole ER and Escitalopram.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as suspended.
